In a nutshell
This study aims to provide both prognostic and predictive biomarkers for prostate cancer by developing new classifications for prostate tumour sub-types.
Why we funded it
Prostate cancer outcomes are extremely variable between patients – some tumours are life-threatening while others are not. Since many drugs have serious side effects, and vary in how well they work for different men, it is important that men and clinicians can make informed choices about which therapy to use in each individual case. This study aims to develop a way of classifying prostate tumours into subtypes that we predict will behave differently in response to existing and novel therapies.
This study has the potential to improve quality of life for men with prostate cancer by helping doctors give a more accurate prognosis and better predict which drugs will work best. This would help avoid unnecessary side effects of inappropriate drugs.
Researcher - Professor Charlotte Bevan
Institution - Imperial College London
Grant award - £256,896.00
Reference - PG14-038